期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 12, 期 11, 页码 1589-1598出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.12.11.1589
关键词
arrhythmia; atrial fibrillation; IKur; Kv1.5; potassium channel blockers
Atrial arrhythmias are a common problem in cardiological practice. Despite the availability of several antiarrhythmic drugs there is a medical need for safer and more efficient treatments. The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. This review summarises patents claiming such compounds.-The chemistry and biological data disclosed in these patents are discussed in light of recent work demonstrating the antiarrhythmic effects of Kv1.5 blockers in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据